ADEL Y04
Alternative Names: ADEL-Y04Latest Information Update: 11 Dec 2023
Price :
$50 *
At a glance
- Originator ADEL
- Class Antibodies; Antidementias
- Mechanism of Action Apolipoprotein E4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Metabolic disorders
Most Recent Events
- 11 Dec 2023 Preclinical trials in Alzheimer's disease in South Korea (Parenteral), prior to December 2023 (ADEL pipeline, December 2023)
- 11 Dec 2023 Preclinical trials in Metabolic disorders in South Korea (Parenteral), prior to December 2023 (ADEL pipeline, December 2023)
- 21 Sep 2023 ADEL Y04 is available for licensing as of 21 Sep 2023. https://www.adelpharm.com/adel-y04